Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Morteza Gholami, Ehsan Saboory, Ali Asghar Ahmadi, Mohsen Asouri, Mehrab Nasirikenari & Mostafa Rostamnezhad. (2020) Long-time effects of prenatal morphine, tramadol, methadone, and buprenorphine exposure on seizure and anxiety in immature rats. International Journal of Neuroscience 130:9, pages 898-905.
Read now
Read now
Gabi Koller, Andreas Schwarzer, Kathrin Halfter & Michael Soyka. (2019) Pain management in opioid maintenance treatment. Expert Opinion on Pharmacotherapy 20:16, pages 1993-2005.
Read now
Read now
Andrea Fanelli, Maria Cristina Sorella & Daniela Ghisi. (2018) Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain. Expert Review of Clinical Pharmacology 11:12, pages 1157-1162.
Read now
Read now
Michael Soyka. (2017) Treatment of opioid dependence with buprenorphine: current update. Dialogues in Clinical Neuroscience 19:3, pages 299-308.
Read now
Read now
Mellar P. Davis. (2016) Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain. Expert Opinion on Drug Metabolism & Toxicology 12:7, pages 823-831.
Read now
Read now
Michael Soyka. (2015) New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone. Substance Abuse and Rehabilitation 6, pages 1-14.
Read now
Read now
Michael Soyka. (2015) Buprenorphine–naloxone buccal soluble film for the treatment of opioid dependence: current update. Expert Opinion on Drug Delivery 12:2, pages 339-347.
Read now
Read now
Robert B Raffa, Robert Taylor$suffix/text()$suffix/text() & Joseph V Pergolizzi$suffix/text()$suffix/text(). (2014) Sequestered naltrexone in sustained release morphine or oxycodone – a way to inhibit illicit use?. Expert Opinion on Drug Safety 13:2, pages 181-190.
Read now
Read now
Michael Soyka. (2012) Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence. Expert Opinion on Drug Delivery 9:11, pages 1409-1417.
Read now
Read now
Sharon Stancliff, Herman Joseph, Chunki Fong, Terry Furst, SandraD. Comer & Perrine Roux. (2012) Opioid Maintenance Treatment as a Harm Reduction Tool for Opioid-Dependent Individuals in New York City: The Need to Expand Access to Buprenorphine/Naloxone in Marginalized Populations. Journal of Addictive Diseases 31:3, pages 278-287.
Read now
Read now
Michael Soyka, Henry R. Kranzler, Wim van den Brink, John Krystal, Hans-Jürgen Möller & Siegfried Kasper. (2011) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. The World Journal of Biological Psychiatry 12:3, pages 160-187.
Read now
Read now
Articles from other publishers (19)
Yatan Pal Singh Balhara, Priyanka Saha, Merlin Mathew, Mukul Kumar, Arpit Parmar, Rakesh Lal & Siddharth Sarkar. (2023) Nonprescription use of buprenorphine tablets among patients at a tertiary care addictive disorder treatment center in India: Observations and implications. Journal of Opioid Management 19:5, pages 403-411.
Crossref
Crossref
Naveen K. Dhagudu, Atul Ambekar, Alok Agrawal, Ravindra Rao, Ashwani K. Mishra, Raka Jain & Shalini Singh. (2020) Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double‐blind, within‐subject, crossover study among opioid‐dependent subjects. Drug and Alcohol Review 39:5, pages 595-603.
Crossref
Crossref
Michael Soyka. 2019. Treatment Resistance in Psychiatry. Treatment Resistance in Psychiatry
179
187
.
Simon Chiu. (2017) Shall we Screen for Cardio-Metabolic Risks in Methadone and Buprenorphine Treatment for Opiate Dependence?. MOJ Addiction Medicine & Therapy 3:1.
Crossref
Crossref
Michael Soyka, Jens Strehle, Jürgen Rehm, Gerhard Bühringer & Hans-Ulrich Wittchen. (2017) Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample. European Addiction Research 23:2, pages 97-105.
Crossref
Crossref
Jonathan P. Caulkins & Peter Reuter. (2017) Dealing More Effectively and Humanely with Illegal Drugs. Crime and Justice 46:1, pages 95-158.
Crossref
Crossref
Michael Soyka & Jochen Mutschler. (2016) Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 70, pages 148-161.
Crossref
Crossref
Essiina Launonen, Hannu Alho, Elina Kotovirta, Isla Wallace & Kaarlo Simojoki. (2015) Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients. International Journal of Drug Policy 26:9, pages 875-882.
Crossref
Crossref
Michael Soyka. (2015) Alcohol Use Disorders in Opioid Maintenance Therapy: Prevalence, Clinical Correlates and Treatment. European Addiction Research 21:2, pages 78-87.
Crossref
Crossref
Michael Soyka, Markus Backmund, Peggy Schmidt & Sabine Apelt. (2014) Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: Results from a 12-month observational study. The American Journal on Addictions 23:6, pages 563-569.
Crossref
Crossref
Theodore J. Cicero, Matthew S. Ellis, Hilary L. Surratt & Steven P. Kurtz. (2014) Factors contributing to the rise of buprenorphine misuse: 2008–2013. Drug and Alcohol Dependence 142, pages 98-104.
Crossref
Crossref
Debasish Basu. (2013)
Commentary on Rosenthal
et al
. (2013): Buprenorphine implant-new hopes, old questions
. Addiction 108:12, pages 2150-2151.
Crossref
Crossref
Zachary McCormick, Samuel K. Chu, George C. Chang-Chien & Petra Joseph. (2013) Acute Pain Control Challenges with Buprenorphine/Naloxone Therapy in a Patient with Compartment Syndrome Secondary to McArdle's Disease: A Case Report and Review. Pain Medicine 14:8, pages 1187-1191.
Crossref
Crossref
Michael Soyka. (2013) Buprenorphine Use in Pregnant Opioid Users: A Critical Review. CNS Drugs 27:8, pages 653-662.
Crossref
Crossref
Hanna Uosukainen, Hannu Pentikäinen & Ulrich Tacke. (2013) The effect of an electronic medicine dispenser on diversion of buprenorphine-naloxone—experience from a medium-sized Finnish city. Journal of Substance Abuse Treatment 45:1, pages 143-147.
Crossref
Crossref
Robert B. Raffa, Joseph V. Pergolizzi, Edmundo Muñiz, Robert Taylor & Jason Pergolizzi. (2012) Designing Opioids That Deter Abuse. Pain Research and Treatment 2012, pages 1-10.
Crossref
Crossref
AR Lingford-Hughes, S Welch, L Peters & DJ Nutt. (2012) BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. Journal of Psychopharmacology 26:7, pages 899-952.
Crossref
Crossref
Briony Larance, Louisa Degenhardt, Nick Lintzeris, James Bell, Adam Winstock, Paul Dietze, Richard Mattick, Robert Ali & Danielle Horyniak. (2011) Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug and Alcohol Dependence 118:2-3, pages 265-273.
Crossref
Crossref
F.J. Álvarez-González. (2009) Buprenorfina-naloxona: lo nuevo de 2009. Trastornos Adictivos 11:4, pages 247-251.
Crossref
Crossref